In this month's issue, Weber et al. 1 reported the results of a single-center retrospective study of two cohorts of patients receiving allogeneic stem cell transplantation (allo-SCT) treated with different prophylactic antibiotic regimens.
The potential of antibiotics to modulate outcomes after allo-SCT was first observed in mouse models 2, 3 followed by clinical studies. 4, 5 In both types of studies, intestinal bacteria were found to contribute to acute GvHD, and total decontamination led to a benefit. Subsequent clinical studies, however, did not consistently demonstrate a reduction in GvHD from antibiotics, possibly due to unreliable total decontamination. 6 Total gut decontamination is now routinely attempted at only a small minority of transplant centers and has been largely supplanted by fluoroquinolonebased prophylaxis. Ciprofloxacin and levofloxacin are both commonly used based on many studies of neutropenic patients with cancer, where fluoroquinolone use prevented febrile events and bloodstream infections, and a meta-analysis was associated with a reduction in all-cause mortality. 7 An alternative to fluoroquinolone-based prophylaxis practiced at some transplant centers involves the addition of metronidazole, which in a single-center prospective randomized study, was found to reduce the development of acute GvHD. 8 The use of prophylactic metronidazole, however, has recently come under scrutiny due to several recent findings: use of metronidazole was associated with loss of intestinal microbiota diversity and an expansion of Enterococcus during allo-SCT, 9 and loss of intestinal microbiota diversity is associated with poor outcomes after allo-SCT; 10 this loss of diversity can manifest as expansion of intestinal Enterococcus, which was associated with active or subsequent gastrointestinal GvHD, 11 or alternatively as loss of a common obligately anaerobic commensal from the genus Blautia, 10 which often preceded subsequent GvHD-related mortality. 12 In response to these findings, the transplant center in Regensburg, Germany, chose to switch their institutional practice from prophylaxis with ciprofloxacin and metronidazole to rifaximin, in 2012. A poorly absorbed member of the rifamycin family, rifaximin has activity against staphylococcal, streptococcal and enterococcal species but has lesser activity against species of Enterobacteriaceae. 13 It has been widely utilized to treat a variety of gastrointestinal conditions, 14 including irritable bowel syndrome and inflammatory bowel disease. In patients with hepatic encephalopathy, rifaximin was found to modulate metabolite production by the intestinal microbiota with only modest changes in overall bacterial composition. 15 In the current study, Weber et al. found that, compared with historical controls from the same center treated with ciprofloxacin and metronidazole, patients treated with rifaximin showed significantly improved overall survival, reduced treatment-related mortality and reduced intestinal GvHD. While this was not a prospectively controlled clinical trial, the differences seen are remarkable. Importantly, use of rifaximin was not associated with increased rates of developing fevers or documented infections. Finally, stool samples were prospectively collected and analyzed for measures of microbiota preservation, including urinary 3-indoxyl sulfate and fecal enterococcal PCRs; these showed reduced perturbation of the microbiota in patients who received prophylaxis with rifaximin.
In summary, use of prophylactic rifaximin may be superior to ciprofloxacin and metronidazole in patients undergoing allo-SCT, and additional studies regarding ideal choice of antibiotic prophylaxis in this patient population are warranted.
